Nerissa Kreher - 26 Sep 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: Chief Medical Officer
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol: TRDA
Transactions as of: 26 Sep 2022
Net transactions value: -$113,383
Form type: 4
Filing time: 28 Sep 2022, 17:10:49 UTC
Previous filing: 23 Sep 2022
Next filing: 27 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Options Exercise	$6,443	+3,068	+15%	$2.10^*	23,784	26 Sep 2022	Direct	F1
transaction	TRDA	Common Stock	Sale	$42,131	-2,768	-12%	$15.22	21,016	26 Sep 2022	Direct	F1, F2
transaction	TRDA	Common Stock	Sale	$4,899	-300	-1.4%	$16.33	20,716	26 Sep 2022	Direct	F1, F3
transaction	TRDA	Common Stock	Options Exercise	$5,046	+2,403	+12%	$2.10^*	23,119	27 Sep 2022	Direct	F1
transaction	TRDA	Common Stock	Sale	$36,789	-2,403	-10%	$15.31	20,716	27 Sep 2022	Direct	F1, F4
transaction	TRDA	Common Stock	Options Exercise	$6,556	+3,122	+15%	$2.10^*	23,838	28 Sep 2022	Direct	F1
transaction	TRDA	Common Stock	Sale	$47,610	-3,122	-13%	$15.25	20,716	28 Sep 2022	Direct	F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRDA	Stock Option (Right to Buy)	Options Exercise	$0	-3,068	-12%	$0.000000	21,557	26 Sep 2022	Common Stock	3,068	$2.10	Direct	F1, F6
transaction	TRDA	Stock Option (Right to Buy)	Options Exercise	$0	-2,403	-11%	$0.000000	19,154	27 Sep 2022	Common Stock	2,403	$2.10	Direct	F1, F6
transaction	TRDA	Stock Option (Right to Buy)	Options Exercise	$0	-3,122	-16%	$0.000000	16,032	28 Sep 2022	Common Stock	3,122	$2.10	Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6	25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.